Detalhe da pesquisa
1.
Efficacy and safety of chemotherapy in young patients with advanced gastroesophageal adenocarcinoma: data from the Spanish AGAMENON-SEOM registry.
Gastric Cancer
; 27(1): 131-145, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-37964032
2.
Prognostic significance of performing universal HER2 testing in cases of advanced gastric cancer.
Gastric Cancer
; 20(3): 465-474, 2017 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-27599830
3.
Real-World Outcomes in Patients with Metastatic Colorectal Cancer in Spain: The RWD-ACROSS Study.
Cancers (Basel)
; 15(18)2023 Sep 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-37760572
4.
The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy.
Ther Adv Med Oncol
; 15: 17588359231157641, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-36895850
5.
External validity of clinical trials with diverse trastuzumab-based chemotherapy regimens in advanced gastroesophageal adenocarcinoma: data from the AGAMENON-SEOM registry.
Ther Adv Med Oncol
; 13: 17588359211019672, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34211587
6.
Treatment in esophagogastric junction cancer: Past, present and future. / Tratamientos oncológicos en el cáncer de unión esofagogástrica: pasado, presente y futuro.
Cir Esp (Engl Ed)
; 97(8): 459-464, 2019 Oct.
Artigo
em Inglês, Espanhol
| MEDLINE | ID: mdl-31155142
7.
Tratamientos oncológicos en el cáncer de unión esofagogástrica: pasado, presente y futuro / Treatment in esophagogastric junction cancer: Past, present and future
Cir. Esp. (Ed. impr.)
; 97(8): 459-464, oct. 2019. tab
Artigo
em Espanhol
| IBECS (Espanha) | ID: ibc-187620